# WIA-BIO-006: Tissue Engineering Specification v1.0

> **Standard ID:** WIA-BIO-006
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Biomedical Engineering Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Scaffold Materials and Design](#2-scaffold-materials-and-design)
3. [3D Bioprinting Protocols](#3-3d-bioprinting-protocols)
4. [Bioreactor Systems](#4-bioreactor-systems)
5. [Vascularization Strategies](#5-vascularization-strategies)
6. [Cell Culture and Seeding](#6-cell-culture-and-seeding)
7. [Quality Testing Standards](#7-quality-testing-standards)
8. [Regulatory Requirements](#8-regulatory-requirements)
9. [Implementation Guidelines](#9-implementation-guidelines)
10. [References](#10-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines the comprehensive framework for tissue engineering, covering scaffold design, biofabrication, cell culture, and quality assurance for regenerative medicine applications.

### 1.2 Scope

The standard covers:
- Natural, synthetic, and hybrid biomaterial scaffolds
- 3D bioprinting techniques and protocols
- Bioreactor design and operation
- Vascularization and perfusion strategies
- Quality control and regulatory compliance

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - This standard aims to advance tissue engineering to restore health, save lives, and improve quality of life through regenerative medicine accessible to all.

### 1.4 Terminology

- **Scaffold**: Three-dimensional structure that supports cell attachment and tissue formation
- **Bioprinting**: Additive manufacturing process using living cells
- **Bioreactor**: Device that provides controlled environment for tissue culture
- **ECM**: Extracellular matrix - natural scaffold produced by cells
- **Decellularization**: Process of removing cells while preserving ECM structure

---

## 2. Scaffold Materials and Design

### 2.1 Natural Biomaterials

#### 2.1.1 Collagen

**Properties**:
```
Young's Modulus: 1-10 MPa
Degradation: 2-8 weeks
Porosity: 70-95%
Cell Adhesion: Excellent (RGD domains)
```

**Applications**: Skin, bone, cartilage, vascular grafts

**Preparation**:
1. Extract from animal sources (bovine, porcine)
2. Purify via salt precipitation
3. Neutralize to pH 7.4
4. Cross-link if needed (EDC, genipin)

#### 2.1.2 Gelatin

**Properties**:
```
Young's Modulus: 0.1-1 MPa
Degradation: 1-4 weeks
Gelation Temperature: 20-30°C
Biocompatibility: Excellent
```

**Advantages**:
- Low immunogenicity
- Thermoresponsive gelation
- Cost-effective
- Easy to process

#### 2.1.3 Chitosan

**Properties**:
```
Young's Modulus: 1-2 GPa
Degradation: 4-12 weeks
pH-responsive: Yes
Antimicrobial: Yes
```

**Processing**:
- Dissolve in acidic solution (pH 5-6)
- Freeze-dry for porous structures
- Can be blended with other polymers

#### 2.1.4 Alginate

**Properties**:
```
Ionic cross-linking: Ca²⁺, Ba²⁺
Gelation: Instantaneous
Young's Modulus: 10-100 kPa
Biocompatibility: Good
```

### 2.2 Synthetic Biomaterials

#### 2.2.1 Polycaprolactone (PCL)

**Properties**:
```
Young's Modulus: 200-400 MPa
Degradation: 6-24 months
Melting Point: 60°C
Hydrophobicity: High
```

**Advantages**:
- FDA approved
- Excellent mechanical properties
- Slow degradation (matches bone healing)
- Easy to process (electrospinning, 3D printing)

#### 2.2.2 Polylactic Acid (PLA)

**Properties**:
```
Young's Modulus: 2-4 GPa
Degradation: 6-12 months
Glass Transition: 60-65°C
Crystallinity: 37%
```

**Applications**: Bone, cartilage, temporary implants

#### 2.2.3 Polyglycolic Acid (PGA)

**Properties**:
```
Young's Modulus: 7 GPa
Degradation: 2-4 weeks
Highly crystalline: 45-55%
Water soluble: Yes
```

**Uses**: Fast-degrading applications, sutures

### 2.3 Hybrid Scaffolds

#### 2.3.1 PCL-Collagen Composite

```
Composition: 70% PCL + 30% Collagen
Young's Modulus: 50-150 MPa
Porosity: 65-80%
Degradation: 3-6 months
```

**Benefits**:
- Combines mechanical strength (PCL) with bioactivity (collagen)
- Tunable degradation rate
- Enhanced cell adhesion

#### 2.3.2 Gelatin-Alginate Blend

```
Ratio: 1:1 to 3:1 (gelatin:alginate)
Gelation: Dual (thermal + ionic)
Mechanical Strength: 10-50 kPa
Injectable: Yes
```

### 2.4 Scaffold Architecture

#### 2.4.1 Porosity Design

```
P = (1 - ρ_apparent / ρ_material) × 100%
```

Where:
- `P` = Porosity (%)
- `ρ_apparent` = Apparent density (g/cm³)
- `ρ_material` = Material density (g/cm³)

**Recommended ranges**:
- Bone: 60-80%
- Cartilage: 70-85%
- Skin: 80-95%
- Liver: 85-90%

#### 2.4.2 Pore Size

```
d_pore = (6 × V_void / S_pore)
```

Where:
- `d_pore` = Average pore diameter (μm)
- `V_void` = Void volume (mm³)
- `S_pore` = Pore surface area (mm²)

**Optimal pore sizes**:
- Osteoblasts: 100-400 μm
- Fibroblasts: 50-150 μm
- Endothelial cells: 30-100 μm
- Hepatocytes: 20-50 μm

#### 2.4.3 Interconnectivity

Minimum interconnectivity: **90%**

```
I = (N_connected / N_total) × 100%
```

Where:
- `I` = Interconnectivity (%)
- `N_connected` = Connected pores
- `N_total` = Total pores

### 2.5 Mechanical Properties

#### 2.5.1 Compression Testing

```
σ = F / A₀
ε = ΔL / L₀
E = σ / ε
```

Where:
- `σ` = Compressive stress (Pa)
- `F` = Applied force (N)
- `A₀` = Initial cross-sectional area (m²)
- `ε` = Strain (dimensionless)
- `ΔL` = Change in length (m)
- `L₀` = Initial length (m)
- `E` = Young's modulus (Pa)

#### 2.5.2 Tissue-Specific Requirements

| Tissue | Young's Modulus | Ultimate Strength | Strain at Failure |
|--------|----------------|-------------------|-------------------|
| Bone | 10-20 GPa | 100-200 MPa | 1-3% |
| Cartilage | 0.5-2 MPa | 5-25 MPa | 10-20% |
| Skin | 0.1-2 MPa | 1-20 MPa | 30-70% |
| Liver | 0.5-1 kPa | 1-5 kPa | 20-40% |
| Cardiac | 10-50 kPa | 10-100 kPa | 15-30% |

---

## 3. 3D Bioprinting Protocols

### 3.1 Bioprinting Technologies

#### 3.1.1 Extrusion-Based Bioprinting

**Principle**: Pneumatic or mechanical extrusion of bioink

**Parameters**:
```
Pressure: 10-200 kPa
Nozzle diameter: 100-1000 μm
Print speed: 5-50 mm/s
Layer height: 50-500 μm
Temperature: 4-37°C
```

**Advantages**:
- High cell density (10⁶-10⁸ cells/mL)
- Multiple materials
- Cost-effective

**Limitations**:
- Lower resolution
- Shear stress on cells

#### 3.1.2 Inkjet Bioprinting

**Principle**: Droplet-based deposition (thermal or piezoelectric)

**Parameters**:
```
Droplet volume: 1-300 pL
Frequency: 1-10 kHz
Resolution: 20-100 μm
Viscosity: 3-12 mPa·s
Cell viability: >85%
```

**Advantages**:
- High resolution
- High speed
- Low cost

#### 3.1.3 Laser-Assisted Bioprinting

**Principle**: Laser-induced forward transfer (LIFT)

**Parameters**:
```
Laser wavelength: 532-1064 nm
Pulse duration: 10-100 ns
Energy: 1-100 μJ/pulse
Resolution: <10 μm
Cell viability: >95%
```

**Advantages**:
- Highest resolution
- Minimal cell damage
- No nozzle clogging

**Limitations**:
- High cost
- Complex setup
- Low throughput

### 3.2 Bioink Formulation

#### 3.2.1 Cell-Laden Hydrogels

**Components**:
1. **Polymer base**: Gelatin, alginate, collagen, hyaluronic acid
2. **Cross-linker**: Ca²⁺, light (405 nm), temperature
3. **Cells**: 10⁶-10⁸ cells/mL
4. **Growth factors**: Optional (VEGF, BMP, FGF)

**Rheological requirements**:
```
Viscosity (η): 30-6000 mPa·s
Shear-thinning: Yes
Storage modulus (G'): 100-10,000 Pa
Loss modulus (G"): 10-1,000 Pa
G' > G" (gel-like behavior)
```

#### 3.2.2 Decellularized ECM Bioinks

**Preparation**:
1. Decellularize tissue (SDS, Triton X-100)
2. Solubilize ECM (pepsin, pH 2-3)
3. Neutralize to pH 7.4
4. Add cells (10⁶-10⁷ cells/mL)

**Properties**:
- Tissue-specific biochemical cues
- Natural architecture
- Enhanced cell function

### 3.3 Bioprinting Protocol

#### 3.3.1 Pre-Print Preparation

1. **Design CAD model** (STL file)
2. **Slice into layers** (10-200 μm)
3. **Generate G-code** (toolpath)
4. **Prepare bioink** (mix cells + hydrogel)
5. **Calibrate printer** (pressure, temperature)
6. **Load cartridges** (maintain sterility)

#### 3.3.2 Printing Process

```
1. Initialize system (UV sterilize)
2. Set parameters:
   - Pressure: 20-100 kPa
   - Speed: 10-30 mm/s
   - Temperature: 15-25°C
3. Prime nozzle (remove air bubbles)
4. Print first layer (adhesion critical)
5. Continue layer-by-layer
6. Monitor visually (camera)
7. Cross-link if needed (UV, Ca²⁺)
```

#### 3.3.3 Post-Print Processing

1. **Cross-linking**: UV (5-15 min), ionic, thermal
2. **Culture medium addition**: Supplement with nutrients
3. **Incubation**: 37°C, 5% CO₂
4. **Maturation**: 1-4 weeks in bioreactor

### 3.4 Quality Control for Bioprinting

**Print fidelity**:
```
F = (1 - |D_actual - D_design| / D_design) × 100%
```

Where:
- `F` = Fidelity (%)
- `D_actual` = Actual dimension
- `D_design` = Designed dimension

**Target**: F > 90%

**Cell viability post-print**:
- Minimum: 80%
- Target: >90%

---

## 4. Bioreactor Systems

### 4.1 Bioreactor Types

#### 4.1.1 Spinner Flask

**Design**:
- Magnetic stirrer
- Suspended scaffolds
- Volume: 50-500 mL

**Advantages**:
- Simple setup
- Low cost
- Dynamic culture

**Parameters**:
```
Rotation speed: 40-100 rpm
Medium volume: 100-250 mL
Exchange rate: 50% daily
Duration: 1-4 weeks
```

#### 4.1.2 Perfusion Bioreactor

**Design**:
- Continuous medium flow through scaffold
- Peristaltic pump
- Oxygen/nutrient control

**Flow rate calculation**:
```
Q = v × A
```

Where:
- `Q` = Flow rate (mL/min)
- `v` = Flow velocity (mm/s)
- `A` = Cross-sectional area (mm²)

**Typical parameters**:
```
Flow rate: 0.1-5 mL/min
Shear stress: 0.1-10 dyne/cm²
Pressure: <10 kPa
Medium exchange: Continuous
```

#### 4.1.3 Rotating Wall Vessel

**Design**:
- Horizontal rotation
- Low shear environment
- Simulated microgravity

**Applications**:
- Cartilage tissue
- Hepatic tissue
- Stem cell differentiation

**Parameters**:
```
Rotation: 15-40 rpm
Volume: 10-55 mL
Culture time: 2-6 weeks
```

#### 4.1.4 Compression Bioreactor

**Design**:
- Cyclic mechanical loading
- For load-bearing tissues

**Loading parameters**:
```
Frequency: 0.1-1 Hz
Strain: 5-15%
Duration: 1-4 hours/day
Rest period: 20-23 hours
```

**Applications**: Bone, cartilage, ligament, tendon

### 4.2 Culture Conditions

#### 4.2.1 Temperature Control

```
T_optimal = 37°C ± 0.5°C
```

**Monitoring**: RTD sensors, ±0.1°C accuracy

#### 4.2.2 pH Control

```
pH_optimal = 7.2-7.6
```

**Control methods**:
- CO₂ regulation (5-10%)
- HEPES buffer (10-25 mM)
- Automated pH monitoring

#### 4.2.3 Oxygen Tension

```
pO₂ = 2-20% (tissue-dependent)
```

**Tissue-specific**:
- Bone: 5-10%
- Cartilage: 2-5%
- Liver: 10-20%
- Cardiac: 5-15%

**Hypoxia benefits**:
- Stem cell maintenance
- Chondrogenesis
- Angiogenesis stimulation

#### 4.2.4 Nutrient Supply

**Glucose consumption**:
```
r_glucose = k × C_cells
```

Where:
- `r_glucose` = Consumption rate (mol/L/h)
- `k` = Specific consumption rate
- `C_cells` = Cell concentration

**Medium composition**:
- DMEM/F12 base
- 10% FBS (or serum-free)
- 1% penicillin/streptomycin
- Growth factors (tissue-specific)

### 4.3 Monitoring and Control

#### 4.3.1 Real-Time Sensors

| Parameter | Sensor Type | Range | Accuracy |
|-----------|-------------|-------|----------|
| Temperature | RTD | 20-45°C | ±0.1°C |
| pH | Glass electrode | 6-8 | ±0.05 |
| Dissolved O₂ | Optical | 0-100% | ±2% |
| Glucose | Enzymatic | 0-25 mM | ±0.5 mM |
| Lactate | Enzymatic | 0-20 mM | ±0.5 mM |

#### 4.3.2 Automated Feedback Control

**PID controller**:
```
u(t) = K_p × e(t) + K_i × ∫e(t)dt + K_d × de(t)/dt
```

Where:
- `u(t)` = Control signal
- `e(t)` = Error (setpoint - measured)
- `K_p, K_i, K_d` = PID gains

---

## 5. Vascularization Strategies

### 5.1 Importance of Vascularization

**Oxygen diffusion limit**: ~100-200 μm

**Rationale**: Tissues >2 mm thick require blood vessels for:
- Oxygen delivery
- Nutrient supply
- Waste removal
- Integration with host

### 5.2 Prevascularization Methods

#### 5.2.1 Co-Culture with Endothelial Cells

**Protocol**:
1. Seed parenchymal cells (day 0)
2. Add endothelial cells (day 3-7)
   - Ratio: 10:1 to 5:1 (parenchymal:endothelial)
3. Culture 7-14 days
4. Observe vessel formation (CD31 staining)

**Growth factors**:
- VEGF: 10-50 ng/mL
- bFGF: 5-20 ng/mL
- Ang-1: 50-100 ng/mL

#### 5.2.2 Microfluidic Channels

**Design**:
```
Channel diameter: 50-500 μm
Spacing: 200-1000 μm
Pattern: Branched network
Flow rate: 0.01-1 mL/min
```

**Fabrication**:
- Sacrificial material (gelatin, Pluronic F127)
- Coaxial printing
- Laser ablation

**Endothelialization**:
1. Seed endothelial cells in channels
2. Rotate bioreactor (uniform coverage)
3. Flow medium after 24-48 hours
4. Mature 5-10 days

#### 5.2.3 Growth Factor Delivery

**Sustained release**:
```
M_t / M_∞ = 1 - exp(-kt)
```

Where:
- `M_t` = Amount released at time t
- `M_∞` = Total amount
- `k` = Release rate constant

**Delivery systems**:
- Microspheres (PLGA)
- Hydrogel encapsulation
- Affinity binding (heparin)

### 5.3 In Vivo Vascularization

#### 5.3.1 Arteriovenous Loop

**Procedure**:
1. Create vascular loop (femoral artery-vein)
2. Embed in tissue construct
3. Implant subcutaneously
4. Allow 2-4 weeks for vessel ingrowth
5. Transfer to target site

**Advantages**:
- Rapid vascularization (7-14 days)
- Mature vessels
- Functional perfusion

#### 5.3.2 Angiogenic Factor Induction

**Host-mediated approach**:
- Implant construct with VEGF
- Host vessels infiltrate
- Integration over 2-6 weeks

**Factors**:
- VEGF: 0.1-10 μg
- bFGF: 0.5-5 μg
- PDGF: 0.1-1 μg

---

## 6. Cell Culture and Seeding

### 6.1 Cell Sources

#### 6.1.1 Primary Cells

**Advantages**:
- Native phenotype
- Tissue-specific function

**Limitations**:
- Limited expansion
- Donor variability
- Ethical considerations

#### 6.1.2 Stem Cells

**Types**:
- **Embryonic stem cells (ESCs)**: Pluripotent, ethical concerns
- **Mesenchymal stem cells (MSCs)**: Multipotent, bone marrow/adipose
- **Induced pluripotent stem cells (iPSCs)**: Patient-specific, reprogrammed

**Differentiation protocols**: Tissue-specific growth factors, mechanical cues

#### 6.1.3 Cell Lines

**Examples**:
- NIH 3T3 (fibroblasts)
- HepG2 (hepatocytes)
- MC3T3 (osteoblasts)

**Advantages**:
- Unlimited supply
- Reproducibility
- Cost-effective

### 6.2 Cell Seeding Methods

#### 6.2.1 Static Seeding

**Protocol**:
1. Prepare cell suspension (10⁶-10⁷ cells/mL)
2. Pipette onto scaffold
3. Incubate 2-4 hours (attachment)
4. Add culture medium
5. Flip scaffold (optional, for uniform seeding)

**Efficiency**: 20-50%

#### 6.2.2 Dynamic Seeding

**Spinner flask method**:
1. Place scaffold in spinner flask
2. Add cell suspension
3. Rotate at 50 rpm for 4-8 hours
4. Transfer to static culture

**Efficiency**: 40-70%

#### 6.2.3 Vacuum Seeding

**Protocol**:
1. Place scaffold in vacuum chamber
2. Add cell suspension
3. Apply vacuum (50-100 kPa, 5-10 min)
4. Release vacuum (cells drawn into pores)

**Efficiency**: 60-90%

#### 6.2.4 Centrifugal Seeding

**Parameters**:
```
RCF = 1.12 × r × (RPM/1000)²
```

Where:
- `RCF` = Relative centrifugal force (×g)
- `r` = Radius (mm)
- `RPM` = Revolutions per minute

**Protocol**:
- Centrifuge at 100-500 ×g for 5-10 min
- Efficiency: 70-95%

### 6.3 Cell Density Optimization

```
D_optimal = f(tissue type, scaffold porosity, culture duration)
```

**Guidelines**:
- **Bone**: 5 × 10⁶ - 2 × 10⁷ cells/cm³
- **Cartilage**: 2 × 10⁷ - 6 × 10⁷ cells/cm³
- **Skin**: 1 × 10⁶ - 5 × 10⁶ cells/cm²
- **Liver**: 5 × 10⁷ - 2 × 10⁸ cells/cm³

---

## 7. Quality Testing Standards

### 7.1 Sterility Testing

**Methods**:
- **USP <71>**: 14-day incubation in media
- **Endotoxin**: LAL assay (<0.5 EU/mL)
- **Mycoplasma**: PCR or culture

**Frequency**: Every batch

### 7.2 Cell Viability Assays

#### 7.2.1 Live/Dead Staining

**Reagents**:
- Calcein AM (live cells, green)
- Ethidium homodimer-1 (dead cells, red)

**Protocol**:
1. Incubate 15-30 min
2. Image with fluorescence microscopy
3. Quantify with ImageJ

**Acceptance**: >80% viability

#### 7.2.2 MTT/MTS Assay

**Principle**: Metabolic activity

```
Viability (%) = (A_sample / A_control) × 100%
```

**Protocol**:
1. Add MTT/MTS reagent
2. Incubate 1-4 hours
3. Measure absorbance (490-570 nm)

### 7.3 Mechanical Testing

#### 7.3.1 Compression Testing

**Standard**: ASTM D1621

**Parameters**:
- Strain rate: 0.5-1 mm/min
- Preload: 0.01-0.1 N
- Deformation: 10-50%

**Outputs**:
- Young's modulus (E)
- Ultimate strength (σ_max)
- Strain at failure (ε_f)

#### 7.3.2 Tensile Testing

**Standard**: ASTM D638

**Parameters**:
- Gauge length: 10-50 mm
- Strain rate: 1-10 mm/min
- Sample shape: Dumbbell

### 7.4 Biocompatibility Testing

#### 7.4.1 Cytotoxicity (ISO 10993-5)

**Extract test**:
1. Incubate material in medium (24h, 37°C)
2. Expose cells to extract
3. Measure viability (MTT, LDH)

**Acceptance**: >70% viability relative to control

#### 7.4.2 Immunogenicity

**Assays**:
- Cytokine release (IL-1β, IL-6, TNF-α)
- T-cell proliferation
- Complement activation (C3a, C5a)

**Target**: <2-fold increase vs. control

#### 7.4.3 In Vivo Biocompatibility

**Subcutaneous implantation**:
- Duration: 1-12 weeks
- Histology: H&E, Masson's trichrome
- Grading: ISO 10993-6

**Scores**:
- 0: No reaction
- 1: Minimal reaction
- 2-4: Increasing severity

**Acceptance**: Score ≤1

### 7.5 Functional Assays

#### 7.5.1 Tissue-Specific Markers

**Bone**:
- Alkaline phosphatase (ALP)
- Osteocalcin (OCN)
- Calcium deposition (Alizarin Red)

**Cartilage**:
- Glycosaminoglycans (GAG, Alcian Blue)
- Collagen type II (immunostaining)
- Aggrecan (Western blot)

**Liver**:
- Albumin secretion (ELISA)
- Urea synthesis (colorimetric assay)
- CYP450 activity (luminescent assay)

#### 7.5.2 Genetic Expression

**qRT-PCR**:
- Extract RNA (TRIzol)
- Reverse transcribe (cDNA)
- Quantify genes (SYBR Green)
- Normalize to housekeeping genes (GAPDH, β-actin)

**Fold change**:
```
FC = 2^(-ΔΔCt)
```

---

## 8. Regulatory Requirements

### 8.1 FDA Classification

**Class II**: Most tissue-engineered products
- 510(k) premarket notification
- Good Manufacturing Practice (GMP)
- Quality System Regulation (QSR)

**Class III**: High-risk products
- Premarket Approval (PMA)
- Clinical trials (Phase I-III)

### 8.2 Good Manufacturing Practice (GMP)

**Requirements**:
- Validated processes
- Controlled environment (ISO 5-7 cleanroom)
- Documented procedures (SOPs)
- Traceability (batch records)
- Quality control (in-process testing)

### 8.3 Preclinical Testing

**Sequence**:
1. In vitro biocompatibility (ISO 10993)
2. Small animal models (rat, rabbit)
3. Large animal models (pig, sheep)
4. Dose-response studies
5. Long-term safety (6-12 months)

### 8.4 Clinical Trials

**Phase I**: Safety (10-30 patients)
**Phase II**: Efficacy (30-100 patients)
**Phase III**: Confirmatory (100-1000 patients)

**Endpoints**:
- Primary: Safety, efficacy
- Secondary: Quality of life, cost-effectiveness

---

## 9. Implementation Guidelines

### 9.1 Required Components

Any WIA-BIO-006 compliant system must include:

1. **Scaffold Designer**: CAD integration, material selection
2. **Bioreactor Controller**: Parameter monitoring and control
3. **Quality Validator**: Automated testing protocols
4. **Bioprinting Module**: Toolpath generation, cell handling
5. **Documentation System**: GMP-compliant record keeping

### 9.2 API Interface

#### 9.2.1 Design Scaffold

```typescript
interface ScaffoldRequest {
  tissueType: string;
  material: BiomaterialType;
  porosity: number;        // percentage
  poreSize: number;        // micrometers
  dimensions: {
    length: number;        // mm
    width: number;         // mm
    height: number;        // mm
  };
}

interface ScaffoldResponse {
  id: string;
  volume: number;          // mm³
  surfaceArea: number;     // mm²
  cellCapacity: number;    // cells
  mechanicalProperties: MechanicalProperties;
  fabricationMethod: string;
}
```

#### 9.2.2 Optimize Culture

```typescript
interface CultureRequest {
  tissueConstruct: TissueConstruct;
  cellType: string;
  duration: number;        // days
  bioreactorType: string;
}

interface CultureResponse {
  flowRate: number;        // mL/min
  oxygenLevel: number;     // percentage
  temperature: number;     // celsius
  shearStress: number;     // dyne/cm²
  predictedMaturation: number;  // days
  qualityScore: number;    // 0-1
}
```

### 9.3 Data Formats

#### 9.3.1 Scaffold Configuration

```json
{
  "scaffold_id": "SCF-2025-001",
  "material": {
    "type": "pcl-collagen",
    "ratio": "70:30",
    "crosslinking": "EDC"
  },
  "architecture": {
    "porosity": 75,
    "pore_size": 200,
    "interconnectivity": 95
  },
  "dimensions": {
    "length": 10,
    "width": 10,
    "height": 3,
    "unit": "mm"
  },
  "mechanical": {
    "youngs_modulus": 50,
    "ultimate_strength": 5,
    "unit": "MPa"
  }
}
```

### 9.4 Error Handling

Standard error codes:

| Code | Meaning | Action |
|------|---------|--------|
| B001 | Insufficient porosity | Increase pore size |
| B002 | Cell viability too low | Check seeding protocol |
| B003 | Mechanical failure | Strengthen scaffold |
| B004 | Contamination detected | Re-sterilize |
| B005 | Poor vascularization | Add growth factors |
| B006 | Biocompatibility issue | Change material |

---

## 10. References

### 10.1 Scientific Literature

1. Langer, R., Vacanti, J.P. (1993). "Tissue Engineering." Science
2. Murphy, S.V., Atala, A. (2014). "3D Bioprinting of Tissues and Organs." Nature Biotechnology
3. Rouwkema, J., Khademhosseini, A. (2016). "Vascularization in Tissue Engineering." Trends in Biotechnology
4. Hollister, S.J. (2005). "Porous Scaffold Design for Tissue Engineering." Nature Materials
5. Griffith, L.G., Naughton, G. (2002). "Tissue Engineering--Current Challenges." Science

### 10.2 Standards and Regulations

| Standard | Title |
|----------|-------|
| ISO 10993 | Biological evaluation of medical devices |
| ASTM F2150 | Guide for characterization and testing of biomaterial scaffolds |
| ASTM F2603 | Standard guide for interpretation of TEM images |
| ISO 13485 | Quality management systems for medical devices |
| 21 CFR 1271 | FDA regulation of human cells and tissues |

### 10.3 Biomaterial Properties

| Material | Density (g/cm³) | Degradation | Biocompatibility |
|----------|----------------|-------------|------------------|
| Collagen I | 1.35 | 2-8 weeks | Excellent |
| Gelatin | 1.27 | 1-4 weeks | Excellent |
| Chitosan | 1.43 | 4-12 weeks | Good |
| Alginate | 1.60 | 2-8 weeks | Good |
| PCL | 1.15 | 6-24 months | Good |
| PLA | 1.24 | 6-12 months | Good |
| PLGA | 1.34 | 1-6 months | Good |

### 10.4 WIA Standards

- WIA-INTENT: Intent-based tissue engineering requests
- WIA-OMNI-API: Universal biomedical API gateway
- WIA-SOCIAL: Collaborative research protocols
- WIA-BIO-001 to BIO-005: Related biomedical standards

---

## Appendix A: Example Calculations

### A.1 Scaffold Porosity

```
Given:
- Material density: 1.15 g/cm³ (PCL)
- Apparent density: 0.29 g/cm³

Calculation:
P = (1 - 0.29/1.15) × 100%
P = (1 - 0.252) × 100%
P = 74.8%

Result: Porosity is 75%, suitable for cartilage tissue
```

### A.2 Cell Seeding Density

```
Given:
- Scaffold volume: 1.0 cm³
- Target density: 5 × 10⁷ cells/cm³

Calculation:
N_cells = D × V
N_cells = 5 × 10⁷ × 1.0
N_cells = 5 × 10⁷ cells

Suspension preparation:
- Cell concentration: 5 × 10⁶ cells/mL
- Volume needed: 10 mL
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-BIO-006 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*